PMC:7281546 / 4853-5012 JSONTXT

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T25","span":{"begin":119,"end":120},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"ddition, the construction of recombinant PEDV with deletion or mutation of the immune antagonistic regions or sites is a potential strategy to develop PEDV vac"}

{"project":"LitCovid-PubTator","denotations":[{"id":"167","span":{"begin":41,"end":45},"obj":"Species"},{"id":"168","span":{"begin":151,"end":155},"obj":"Species"}],"attributes":[{"id":"A167","pred":"tao:has_database_id","subj":"167","obj":"Tax:28295"},{"id":"A168","pred":"tao:has_database_id","subj":"168","obj":"Tax:28295"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ddition, the construction of recombinant PEDV with deletion or mutation of the immune antagonistic regions or sites is a potential strategy to develop PEDV vac"}